Croixssance Pharma SPRL
Croixssance Pharma reported total assets of 9,474 € at the end of the 2025 financial year (annual accounts filed with the NBB on 16 Jun 2026).
The score of Croixssance Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets -26 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Croixssance Pharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 16 Jun 2026
- Year ended 31 Dec 2024filed on 30 Jun 2025
- Year ended 31 Dec 2023filed on 28 Jun 2024
- Year ended 31 Dec 2022filed on 30 Jun 2023
- Year ended 31 Dec 2021filed on 04 Jul 2022
Croixssance Pharma's financial analysis
- Solvency-158.5%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Croixssance Pharma
Croixssance Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0644.605.976
- VAT number
- BE0644605976
- Peppol
- Registered · 0208:0644605976 · as of 10 Nov 2026
- Legal form
- SPRL
- Incorporated
- 17 Dec 2015
- Registered office
- 1930 Zaventem
- Latest accounts
- 2025 · filed on 16 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Croixssance Pharma (SPRL) has been based in Zaventem since 2015, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 1,861 € and equity of −15,015 €; its revenue is not published. Its solvency stands at -158.5%, below the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Croixssance Pharma
Companies in the same business, of comparable size and area, outside its group.
- Au Pave D' Ollignies Retail sale of pharmaceutical products Mouscron · balance sheet 7,469 €
- Pharma Switch Retail sale of pharmaceutical products Merchtem · balance sheet 9,444 €
- FarmaGill Retail sale of pharmaceutical products Philippeville · balance sheet 8,566 €
- Farmaco Retail sale of pharmaceutical products Ranst · balance sheet 17,325 €
- TVB Consult Retail sale of pharmaceutical products Kruisem · balance sheet 17,370 €
- Camille Huby Retail sale of pharmaceutical products Etterbeek · balance sheet 18,562 €
- PharmaSave Retail sale of pharmaceutical products Antwerp · balance sheet 20,063 €
- Kasibel Retail sale of pharmaceutical products Uccle · balance sheet 20,641 €
Frequently asked questions about Croixssance Pharma
What is the revenue of Croixssance Pharma?
Croixssance Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Croixssance Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0644605976 for Croixssance Pharma, if the company is VAT-registered. Its company number (CBE) is 0644.605.976.
Where is the registered office of Croixssance Pharma?
According to the CBE register, the registered office of Croixssance Pharma is in 1930 Zaventem.
What is the equity of Croixssance Pharma?
At the close of the 2025 financial year, the equity of Croixssance Pharma amounts to -15,015 €, a solvency of -158.5% of total assets.
Who manages Croixssance Pharma?
The register lists 1 active mandates at Croixssance Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Croixssance Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →